The Ledger

BIO

Bio-Rad Laboratories Inc - Class AHealth Careinsider_universe

Last close $366.36Nov 12, 2026

Day −1.11%

Currently held

Agent 20 — SIR Price/Volumelong
5 sh @ $386.89 · stop $354.52
-$102.80 unrealized

Everything we've seen

·Nov 15, 11:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 11:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 11:02 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 10:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 10:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 10:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 10:02 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 9:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 9:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 9:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 9:02 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 8:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 8:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 8:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 8:03 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 7:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 7:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 7:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 7:02 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 6:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 6:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 6:17 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 6:03 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 5:47 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
·Nov 15, 5:32 AMstreamnews
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
?Nov 13, 1:05 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.51% today, which is a moderate but not dramatic move. The lone headline is a generic market research report mentioning Bio-Rad alongside peers — no company-specific catalyst driving the move. Without a clear fundamental driver, the decline may reflect sector rotation or broad tape pressure rather than conviction selling. The macro context shows the 10Y2Y spread printing 2.0σ below its 24-month trend, which is modestly bearish for risk assets but primarily affects Banks and Defensives — not life science tools/diagnostics names like BIO directly. With 160 minutes remaining there is ample time for continuation, but also ample time for a mean-reversion bounce, especially absent a specific negative catalyst. The move has not crossed the 2% threshold that would signal stronger institutional conviction. Balancing the moderate downward momentum against the lack of a clear catalyst and the macro signal being sector-agnostic for BIO, this is a borderline read that falls just below the 0.5 threshold — the absence of a news driver that would sustain the selling pressure tips the edge slightly toward fade rather than continuation.
!Nov 13, 1:05 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 1.51% today, which is a moderate but not dramatic move. The lone headline is a generic market research report mentioning Bio-Rad alongside peers — no company-specific catalyst driving the move. Without a clear fundamental driver, the decline may reflect sector rotation or broad tape pressure rather than conviction selling. The macro context shows the 10Y2Y spread printing 2.0σ below its 24-month trend, which is modestly bearish for risk assets but primarily affects Banks and Defensives — not life science tools/diagnostics names like BIO directly. With 160 minutes remaining there is ample time for continuation, but also ample time for a mean-reversion bounce, especially absent a specific negative catalyst. The move has not crossed the 2% threshold that would signal stronger institutional conviction. Balancing the moderate downward momentum against the lack of a clear catalyst and the macro signal being sector-agnostic for BIO, this is a borderline read that falls just below the 0.5 threshold — the absence of a news driver that would sustain the selling pressure tips the edge slightly toward fade rather than continuation.
❖Nov 13, 9:33 AMnewsvia finnhub
2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox
Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat
?Nov 12, 3:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 20 minutes remaining until the forced 3:45 PM ET close, there is very limited runway for further downside continuation even if momentum is intact. The move is already -3.69%, which is a meaningful intraday decline, but at this stage of the session the dominant risk is mean reversion and short-covering into the close rather than fresh selling pressure. The headlines present are generic industry market research reports with no negative catalyst specific to BIO. The macro context shows T10YIE at 1.7σ below trend (low inflation expectations), which is modestly supportive for long-duration/growth names like BIO, creating a slight headwind against further selling. With a -3.69% move already in the book, late-session profit-taking by shorts and opportunistic dip buyers typically compress further downside in the final 20 minutes. The asymmetry of the forced flatten at 3:45 PM combined with the 20-minute window, absence of a fresh bearish catalyst, and macro conditions that marginally favor the sector push this below the 0.5 threshold.
!Nov 12, 3:25 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
With only 20 minutes remaining until the forced 3:45 PM ET close, there is very limited runway for further downside continuation even if momentum is intact. The move is already -3.69%, which is a meaningful intraday decline, but at this stage of the session the dominant risk is mean reversion and short-covering into the close rather than fresh selling pressure. The headlines present are generic industry market research reports with no negative catalyst specific to BIO. The macro context shows T10YIE at 1.7σ below trend (low inflation expectations), which is modestly supportive for long-duration/growth names like BIO, creating a slight headwind against further selling. With a -3.69% move already in the book, late-session profit-taking by shorts and opportunistic dip buyers typically compress further downside in the final 20 minutes. The asymmetry of the forced flatten at 3:45 PM combined with the 20-minute window, absence of a fresh bearish catalyst, and macro conditions that marginally favor the sector push this below the 0.5 threshold.
?Nov 12, 11:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.25% today with 240 minutes remaining, which is a meaningful intraday move suggesting real selling pressure. However, several factors temper conviction for continuation. The macro context shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations and a low-rate environment — this is generally supportive for growth/life sciences names like Bio-Rad, which argues against aggressive continuation of the selloff. The headlines are generic industry market reports with no company-specific negative catalyst, so the move appears technically or flow-driven rather than news-driven. With 240 minutes remaining there is ample time for either continuation or mean reversion. No clear reversal signal is present, and momentum from a 2.25% decline warrants some respect. On balance, the supportive macro backdrop (low real rates favorable to long-duration biotech/life science equities) provides a mild headwind to further downside, but the existing momentum and absence of a positive catalyst keep the lean modestly toward continuation. Probability is set near the lower end of the continuation range given the macro offset.
!Nov 12, 11:45 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.25% today with 240 minutes remaining, which is a meaningful intraday move suggesting real selling pressure. However, several factors temper conviction for continuation. The macro context shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations and a low-rate environment — this is generally supportive for growth/life sciences names like Bio-Rad, which argues against aggressive continuation of the selloff. The headlines are generic industry market reports with no company-specific negative catalyst, so the move appears technically or flow-driven rather than news-driven. With 240 minutes remaining there is ample time for either continuation or mean reversion. No clear reversal signal is present, and momentum from a 2.25% decline warrants some respect. On balance, the supportive macro backdrop (low real rates favorable to long-duration biotech/life science equities) provides a mild headwind to further downside, but the existing momentum and absence of a positive catalyst keep the lean modestly toward continuation. Probability is set near the lower end of the continuation range given the macro offset.
?Nov 12, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 3.03% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations — this is modestly supportive of longer-duration/growth-oriented names like BIO, which could create a mild headwind against further downside continuation. However, the absence of a bullish catalyst and the fact that a move of this magnitude reflects real selling conviction tips the balance toward modest continuation. With 315 minutes remaining (a full session still ahead), there is ample time for the move to extend. No reversal signals are present in the data. The macro tailwind is too weak to confidently call a fade, so this reads as a low-conviction continuation setup — probability just above the 0.5 threshold.
!Nov 12, 10:30 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 3.03% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows T10YIE at 1.7σ below trend, indicating compressed inflation expectations — this is modestly supportive of longer-duration/growth-oriented names like BIO, which could create a mild headwind against further downside continuation. However, the absence of a bullish catalyst and the fact that a move of this magnitude reflects real selling conviction tips the balance toward modest continuation. With 315 minutes remaining (a full session still ahead), there is ample time for the move to extend. No reversal signals are present in the data. The macro tailwind is too weak to confidently call a fade, so this reads as a low-conviction continuation setup — probability just above the 0.5 threshold.
❖Nov 12, 10:00 AMnewsvia finnhub
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck
Capitalize on demand for automated, high-throughput and single-cell solutions, driven by personalized medicine, proteomics, genomics and biopharma researchDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell lysis and cell fractionation market was valued at US$2.8 billion in 2025 and is projected to reach US$4.5 billion by 2032, expanding at a compound annual growth
❖Nov 12, 9:57 AMnewsvia finnhub
Microfluidic Device Systems - Global Strategic Business Report 2026: Capitalize on 8.7% CAGR to $11.1 Billion by 2032 | Abbott, Danaher, Bio-Rad, and Siemens Healthineers Shape the Competition
Target point-of-care diagnostics, precision medicine and drug discovery; automation, miniaturization and low reagent use can cut costs, speed workflows and support scalable growthDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Microfluidic Device Systems - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global microfluidic device systems market was valued at US$6.2 billion in 2025 and is projected to reach US$11.1 billion by 2032, expanding at a compoun
❖Nov 11, 10:29 AMnewsvia finnhub
Is Illumina Stock Worth The Wait?
For questions about this article or underlying research, email help@trefis.com.
❖Nov 11, 9:21 AMnewsvia finnhub
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
Target equipment and gene-editing delivery opportunities, using regional and competitive insights to prioritize R&D, partnerships and revenue growth.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Transfection Technologies - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global transfection technologies market was valued at US$1.3 billion in 2025 and is projected to reach US$2.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.4%
❖Nov 11, 9:18 AMnewsvia finnhub
Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032
Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Single-Cell Analysis - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-cell analysis market was valued at US$7.1 billion in 2025 and is projected to reach US$26.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 20.4%. Growth is being supported by increasing demand for precision medicine, targeted therapies, biomarker discovery and advanced cellular research across pharma
❖Nov 11, 9:13 AMnewsvia finnhub
Molecular Cytogenetics - Global Strategic Business Report: Capitalize on 8.8% CAGR to US$3.5 Billion by 2030; Outmaneuver Abbott, Agilent, Bio-Rad, Illumina and Roche Amid Tariff Shifts
Capitalize on personalized medicine, advanced genetic testing and cancer diagnostics with tariff-aware sourcing, regional analysis and competitive insights.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Molecular Cytogenetics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global molecular cytogenetics market was valued at US$2.1 billion in 2024 and is projected to reach US$3.5 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.8% fro
✓Nov 10, 5:21 PMdecisionacted
Agent 20 — SIR Price/Volume — buy
[cluster_break_up] From 2026-10-13 through 2026-11-05, BIO's PV path clustered tightly in the $352–$385 range on subdued, largely routine volume (133K–434K, with most days well under 300K). The pullback from the 2026-10-28 high of $385.12 found support around $366–$372 on modest volume (183K–212K), consistent with orderly profit-taking rather than distribution. Today's close of $388.31 on 547K — a volume z-score of +4.21 and 2.26× the 20-day ADV of 242K — represents a decisive break above the top of that multi-week cluster on dramatically expanding volume, the hallmark "cluster_break_up" signature in the SIR 2-D framework. The path's up-and-right trajectory from the 2026-11-06 session ($381.57, 273K) through today further confirms fresh demand absorbing the float rather than a one-off spike. Risks: A retreat back below the $381–$384 cluster ceiling (the 2026-10-28/11-06 highs) on elevated or expanding volume in the next 1–3 sessions would signal a failed breakout and invalidate this read. Additionally, the macro context flags a Fed Funds rate 2.0σ above trend as of 2026-11-06, which could pressure rate-sensitive health care valuations and compress the runway for the breakout to follow through over the 60–90 day horizon.
❖Nov 10, 10:11 AMnewsvia finnhub
Capillary Electrophoresis - Global Strategic Business Report: Secure Share of the $1.1 Billion Market by 2032 as Agilent, Bio-Rad, Danaher and Thermo Fisher Accelerate CE-MS Innovation
Capitalize on CE-MS, automation and microchip CE to boost throughput, cut reagent use, and target pharma, biotech, diagnostics and high-growth Asian markets.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Capillary Electrophoresis - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Capillary Electrophoresis Market to Reach US$1.1 Billion by 2032 The global capillary electrophoresis market was valued at US$819.1 million in 2025 and is projected to reach US$1
❖Nov 10, 10:02 AMnewsvia finnhub
Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share
Target automation, magnetic bead and microfluidic platforms for diagnostics, genomics and precision medicine; use tariff insights to optimize sourcing and supply chains.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Nucleic Acid Isolation and Purification - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Nucleic Acid Isolation and Purification Market to Reach US$12 Billion by 2030 The global nucleic acid isolation and purification market was valued at US
❖Nov 10, 9:20 AMnewsvia finnhub
Gene Amplification Technologies - Global Strategic Business Report: Capture $4.4B in New Revenue by 2030 as Abbott, Bio-Rad, bioMerieux, Cepheid and Becton Dickinson Battle for Share
Target personalized medicine, diagnostics and pharma R&D with PCR, NGS and CRISPR innovation; tariff, regional and competitive insights reveal revenue opportunities.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Gene Amplification Technologies - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global gene amplification technologies market, valued at US$5.7 billion in 2024, is projected to reach US$10.1 billion by 2030. This represents a compound annual growt
❖Nov 10, 7:41 AMnewsvia finnhub
Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript
Bio-Rad Laboratories, Inc. (BIO) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM ESTCompany ParticipantsRoop Lakkaraju - Executive VP &...
❖Nov 10, 7:11 AMnewsvia finnhub
Why Is Bio Rad Laboratories (BIO) Drawing Elliott’s Attention Now?
Elliott Investment Management has taken an activist position in Bio-Rad Laboratories (NYSE:BIO), pushing for changes at the diagnostics group. The investor is calling out what it views as hidden value at Bio-Rad, including the company’s stake in Sartorius. Elliott is also urging a review of operations and capital allocation, which could lead to restructuring or asset monetization moves. The new activist pressure from Elliott on Bio-Rad’s operations and Sartorius stake is important, but it...
❖Nov 10, 6:08 AMnewsvia finnhub
How Investors Are Reacting To Bio Rad (BIO) International Revenue Surprise
Bio-Rad Laboratories reported third quarter 2026 sales of US$656.4 million and net income of US$458.6 million, compared with a loss a year earlier, alongside a US$49.8 million impairment of purchased intangibles. The swing from loss to profit, supported by stronger international revenue surprises in Asia and EMEA, highlights how overseas demand is influencing Bio-Rad Laboratories' current earnings mix. The focus now is on how this sharp earnings turnaround at Bio-Rad Laboratories could...
?Nov 9, 3:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 5 minutes remaining until the forced 3:45 PM ET close, there is virtually no time for the move to extend meaningfully. The 2.31% gain is a solid intraday move suggesting real conviction, but the extreme time constraint dominates all other factors. Even a perfect setup cannot generate meaningful continuation in 5 minutes, and the risk of end-of-day profit-taking or mean reversion in the final minutes is real. No supporting news catalysts and macro context (elevated mortgage rates) is not relevant to BIO (biotechnology). Probability falls below the 0.5 threshold purely on time-remaining grounds.
!Nov 9, 3:40 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
With only 5 minutes remaining until the forced 3:45 PM ET close, there is virtually no time for the move to extend meaningfully. The 2.31% gain is a solid intraday move suggesting real conviction, but the extreme time constraint dominates all other factors. Even a perfect setup cannot generate meaningful continuation in 5 minutes, and the risk of end-of-day profit-taking or mean reversion in the final minutes is real. No supporting news catalysts and macro context (elevated mortgage rates) is not relevant to BIO (biotechnology). Probability falls below the 0.5 threshold purely on time-remaining grounds.
❖Nov 9, 8:15 AMnewsvia finnhub
Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention
Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
❖Nov 9, 6:00 AMnewsvia finnhub
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for clinical laboratoriesLOUISVILLE, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced it will present new data from its tumor-informed and tumor-naïve molecular monitoring programs at the Association for Molecular Pathology (AM
?Nov 5, 5:21 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path traced a clear arc: accumulation from the Oct 16 low (~$352–354) through Oct 28 peak ($385.12 on 251K), but the rally was notably low-volume — six consecutive up-days from Oct 21–28 printed volumes ranging only 167K–361K against a 20-day ADV of 222K, with most sessions well below ADV. The distribution signal materialises clearly over the final stretch: today's bar (2026-11-05) printed 695K — a z-score of 7.87 — on a -3.08% decline to $368.30, the highest single-day volume in the entire 20-day window by a wide margin. Crucially, the 3-session sub-path (Nov 03–05) shows net negative price movement (+2.39%, +1.35%, -3.08% = net -0.34%) on sharply expanding volume (214K → 282K → 695K), satisfying two of the three bearish-confirmation criteria required even under a bull-regime asymmetric burden: (1) price was near a multi-week high with today's volume at 3.1× the 20-day ADV, and (2) the last 3 sessions show net negative price action on expanding volume. Risks: This bearish read would be invalidated if BIO reclaims $374–$380 on above-average volume in the next 1–3 sessions, suggesting today's 695K bar was a capitulative flush rather than distribution. Additionally, the macro context (elevated DFF, +2.1σ above trend) could disproportionately weigh on Health Care via discount-rate pressure, but a sudden rate pivot or sector rotation into defensives could quickly reverse this signal.
?Nov 5, 2:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.81% today with no attributable news catalyst, suggesting institutional selling or sector rotation rather than a news-driven event. The macro context shows elevated DFF (3.88, +2.1σ above trend), which primarily pressures rate-sensitive sectors like banks and money markets — BIO (Bio-Rad Laboratories) as a life sciences/diagnostics name is not a primary reactor to fed funds rate spikes, so macro context is marginally unhelpful for explaining or extending the move. With 70 minutes remaining, there is enough time for a continuation but also for a mean-reversion bounce, especially since the move is already approaching the -3% threshold where short-term oversold conditions can attract dip buyers. No headlines to confirm sustained selling pressure, volume data not available to confirm conviction. The move is meaningful (nearly -3%) and the default lean per system rules is toward continuation, but the lack of news, the macro context being non-sector-specific, and the modest risk of a late-day bounce keep this at the threshold rather than a high-conviction read. Assigning 0.50 — borderline continuation, triggering a position per system rules but with no strong edge beyond momentum alone.
!Nov 5, 2:36 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.81% today with no attributable news catalyst, suggesting institutional selling or sector rotation rather than a news-driven event. The macro context shows elevated DFF (3.88, +2.1σ above trend), which primarily pressures rate-sensitive sectors like banks and money markets — BIO (Bio-Rad Laboratories) as a life sciences/diagnostics name is not a primary reactor to fed funds rate spikes, so macro context is marginally unhelpful for explaining or extending the move. With 70 minutes remaining, there is enough time for a continuation but also for a mean-reversion bounce, especially since the move is already approaching the -3% threshold where short-term oversold conditions can attract dip buyers. No headlines to confirm sustained selling pressure, volume data not available to confirm conviction. The move is meaningful (nearly -3%) and the default lean per system rules is toward continuation, but the lack of news, the macro context being non-sector-specific, and the modest risk of a late-day bounce keep this at the threshold rather than a high-conviction read. Assigning 0.50 — borderline continuation, triggering a position per system rules but with no strong edge beyond momentum alone.
?Nov 5, 11:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.00% today with no headline catalyst, suggesting this is either sector/macro-driven or institutional flow. The macro context shows DFF running 2.1σ above trend — elevated rates environment is modestly negative for growth/biotech names like BIO, providing a mild tailwind for continued selling pressure. With 230 minutes remaining, there is ample time for the move to extend. However, the absence of any news makes it harder to assign high conviction — without a clear narrative, fades are more common in mid-cap biotech names after a 2% drop. No reversal signals are evident from the data provided, and the magnitude (2%) is meaningful but not extreme. Overall, slight lean toward continuation given time remaining and macro headwinds, but conviction is low — probability just above the trigger threshold.
!Nov 5, 11:55 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.00% today with no headline catalyst, suggesting this is either sector/macro-driven or institutional flow. The macro context shows DFF running 2.1σ above trend — elevated rates environment is modestly negative for growth/biotech names like BIO, providing a mild tailwind for continued selling pressure. With 230 minutes remaining, there is ample time for the move to extend. However, the absence of any news makes it harder to assign high conviction — without a clear narrative, fades are more common in mid-cap biotech names after a 2% drop. No reversal signals are evident from the data provided, and the magnitude (2%) is meaningful but not extreme. Overall, slight lean toward continuation given time remaining and macro headwinds, but conviction is low — probability just above the trigger threshold.
?Nov 5, 10:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 3.33% today, a meaningful intraday move that reflects real institutional selling pressure. There are no headlines to explain the move, but as the guidance notes, absence of news is not a disqualifier — large flows often precede or coincide with information asymmetry. With 345 minutes remaining (essentially a full trading session still ahead), there is ample time for continuation. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-negative and could weigh on higher-multiple healthcare/biotech names like BIO. However, the elevated rate environment is more directly reactive in Banks and Money-market funds, so sector tailwind for further selling is limited. The 3.33% decline is at the lower bound of the 'meaningful' range, suggesting conviction exists but is not overwhelming. No reversal signals are evident from the data provided. Overall, slight lean toward continuation given real selling flow, adequate time remaining, and mild macro headwinds, but no strong catalyst to push conviction higher than the low-50s range.
!Nov 5, 10:01 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 3.33% today, a meaningful intraday move that reflects real institutional selling pressure. There are no headlines to explain the move, but as the guidance notes, absence of news is not a disqualifier — large flows often precede or coincide with information asymmetry. With 345 minutes remaining (essentially a full trading session still ahead), there is ample time for continuation. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly risk-negative and could weigh on higher-multiple healthcare/biotech names like BIO. However, the elevated rate environment is more directly reactive in Banks and Money-market funds, so sector tailwind for further selling is limited. The 3.33% decline is at the lower bound of the 'meaningful' range, suggesting conviction exists but is not overwhelming. No reversal signals are evident from the data provided. Overall, slight lean toward continuation given real selling flow, adequate time remaining, and mild macro headwinds, but no strong catalyst to push conviction higher than the low-50s range.
?Nov 3, 1:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.54% today with no attributable headline catalyst, suggesting this is flow-driven rather than news-driven. The move is meaningful in magnitude but not extreme. Macro context shows DFF elevated 2.2σ above trend — a hawkish rate environment that is mildly negative for growth/biotech names like BIO, creating a modest headwind for continuation. No reversal signals are present in the data provided, and 140 minutes remaining gives reasonable runway for the move to extend to the +3% target. Absence of news does not disqualify the setup. On balance, momentum slightly favors continuation but the elevated rate environment and lack of a clear catalyst keep conviction modest — probability just above the trigger threshold.
!Nov 3, 1:25 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is up 2.54% today with no attributable headline catalyst, suggesting this is flow-driven rather than news-driven. The move is meaningful in magnitude but not extreme. Macro context shows DFF elevated 2.2σ above trend — a hawkish rate environment that is mildly negative for growth/biotech names like BIO, creating a modest headwind for continuation. No reversal signals are present in the data provided, and 140 minutes remaining gives reasonable runway for the move to extend to the +3% target. Absence of news does not disqualify the setup. On balance, momentum slightly favors continuation but the elevated rate environment and lack of a clear catalyst keep conviction modest — probability just above the trigger threshold.
?Oct 23, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.61% today, which is a moderate but not outsized move. There are no catalysts or headlines driving the move, making it harder to assess conviction. The macro context shows a flattening yield curve (T10Y2Y at 1.6σ below trend), which is modestly supportive of defensives but not specifically bearish for BIO (a life sciences/tools sector name). With 355 minutes remaining — essentially a full trading session still ahead — there is ample time for the move to continue, but also ample time for mean reversion. The move size (~1.6%) is meaningful but not extreme enough to signal a dominant directional flush. No reversal pattern is identifiable from available data, and absence of news does not disqualify continuation. On balance, this is a borderline read: modest downside momentum with no clear catalyst to either accelerate or reverse it. Assigning 0.50 — minimal edge for continuation, meets the threshold to take a short position given bounded downside risk and the system's asymmetric payoff structure.
!Oct 23, 9:51 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 1.61% today, which is a moderate but not outsized move. There are no catalysts or headlines driving the move, making it harder to assess conviction. The macro context shows a flattening yield curve (T10Y2Y at 1.6σ below trend), which is modestly supportive of defensives but not specifically bearish for BIO (a life sciences/tools sector name). With 355 minutes remaining — essentially a full trading session still ahead — there is ample time for the move to continue, but also ample time for mean reversion. The move size (~1.6%) is meaningful but not extreme enough to signal a dominant directional flush. No reversal pattern is identifiable from available data, and absence of news does not disqualify continuation. On balance, this is a borderline read: modest downside momentum with no clear catalyst to either accelerate or reverse it. Assigning 0.50 — minimal edge for continuation, meets the threshold to take a short position given bounded downside risk and the system's asymmetric payoff structure.
?Oct 22, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 1.60% today, a modest but real move suggesting some directional flow. With 350 minutes remaining until the forced close, there is ample time for continuation. However, the move is below the 2-5% threshold that would signal strong conviction, so this reads as ordinary momentum rather than a high-conviction setup. No news headlines are present to explain the move, which is neutral per the framework. The macro context shows elevated 2-year yields (4.77, +2.1σ above trend), which is a modest headwind for growth/biotech names like BIO as higher short rates compress valuations and increase the cost of capital for capital-intensive biopharma pipelines. This macro factor modestly pressures the continuation thesis. No reversal pattern is evident from the data provided. On balance, the move has enough time and baseline momentum to warrant a lean toward continuation, but the elevated rate environment and sub-2% move size keep confidence only marginally above the threshold.
!Oct 22, 9:55 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 1.60% today, a modest but real move suggesting some directional flow. With 350 minutes remaining until the forced close, there is ample time for continuation. However, the move is below the 2-5% threshold that would signal strong conviction, so this reads as ordinary momentum rather than a high-conviction setup. No news headlines are present to explain the move, which is neutral per the framework. The macro context shows elevated 2-year yields (4.77, +2.1σ above trend), which is a modest headwind for growth/biotech names like BIO as higher short rates compress valuations and increase the cost of capital for capital-intensive biopharma pipelines. This macro factor modestly pressures the continuation thesis. No reversal pattern is evident from the data provided. On balance, the move has enough time and baseline momentum to warrant a lean toward continuation, but the elevated rate environment and sub-2% move size keep confidence only marginally above the threshold.
?Oct 21, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
A hard veto fires immediately: earnings are imminent in just 6 days (2026-10-27), and none of the three required override conditions are present — there is no insider cluster buy, no unusual call flow data, and the fundamental picture is opaque due to the absence of recent SEC filings or news. The sector context (Health Care ranked #1 of 11 by 30-day relative strength, strongly outperforming SPY) actually suggests the single-stock drop is idiosyncratic rather than sector-wide noise, which is a negative signal. With a binary earnings event days away capable of swinging the stock ±10% or more, the near-term risk/reward is structurally unfavorable for a dip-buy entry.
!Oct 21, 10:20 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
A hard veto fires immediately: earnings are imminent in just 6 days (2026-10-27), and none of the three required override conditions are present — there is no insider cluster buy, no unusual call flow data, and the fundamental picture is opaque due to the absence of recent SEC filings or news. The sector context (Health Care ranked #1 of 11 by 30-day relative strength, strongly outperforming SPY) actually suggests the single-stock drop is idiosyncratic rather than sector-wide noise, which is a negative signal. With a binary earnings event days away capable of swinging the stock ±10% or more, the near-term risk/reward is structurally unfavorable for a dip-buy entry.
?Oct 21, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO (Bio-Rad Laboratories) is down 10.3% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no negative headlines, no adverse SEC filings, and no insider selling. Health Care (XLV) is the strongest sector by 30-day relative strength (+7.19pts vs SPY), suggesting the dip is idiosyncratic rather than sector-driven, which warrants investigation but also implies sector tailwinds could support a recovery. However, the dominant risk here is imminent earnings in 6 days (2026-10-27 after close), which represents a hard binary event that could easily extend the drawdown further; the calibration guidelines explicitly default toward not buying under these conditions unless other evidence is unusually strong.
!Oct 21, 10:20 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO (Bio-Rad Laboratories) is down 10.3% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no negative headlines, no adverse SEC filings, and no insider selling. Health Care (XLV) is the strongest sector by 30-day relative strength (+7.19pts vs SPY), suggesting the dip is idiosyncratic rather than sector-driven, which warrants investigation but also implies sector tailwinds could support a recovery. However, the dominant risk here is imminent earnings in 6 days (2026-10-27 after close), which represents a hard binary event that could easily extend the drawdown further; the calibration guidelines explicitly default toward not buying under these conditions unless other evidence is unusually strong.
?Oct 16, 3:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO (Bio-Rad Laboratories) is down ~10.1% from its 30-day high, a modest and plausible dip without confirmed fundamental impairment — the SEC filings show no adverse metrics and there are no negative headlines. However, the dominant risk factor here is imminent earnings on 2026-10-27 (11 days away), which is a binary event that the framework explicitly treats as a default-skip unless other evidence is unusually strong. No confirming signals exist: zero insider buys, no options flow data, and no analyst upgrades post-drop. Today's broad market sell-off (SPY -1.14%, QQQ -2.44%, VXX +9.13%) partially explains the dip, but Health Care is actually outperforming (rank 2 of 11, +5.65pts vs SPY over 5 days), meaning BIO is underperforming its own sector — a mild idiosyncratic negative. The 10Y at 5.19% is a structural headwind. With no confirmation signals and imminent earnings risk, this setup does not clear the bar.
?Oct 16, 3:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
A hard veto fires due to imminent earnings on 2026-10-27 (11 days away), and none of the three required override conditions are present — there is no insider cluster buy, no unusual call flow, and the fundamental picture is opaque given empty SEC filing metrics. The sector (Health Care/XLV) is actually outperforming the market significantly (rank 2 of 11, +5.65pts vs SPY over 5 days), suggesting the ~10% drop in BIO is idiosyncratic rather than sector-wide, adding a negative signal. The macro environment is also unfavorable with the 10Y at 5.19% (above the 4.5% threshold) and today's broad market selloff (SPY -1.14%, VXX +9.13%).
!Oct 16, 3:21 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
A hard veto fires due to imminent earnings on 2026-10-27 (11 days away), and none of the three required override conditions are present — there is no insider cluster buy, no unusual call flow, and the fundamental picture is opaque given empty SEC filing metrics. The sector (Health Care/XLV) is actually outperforming the market significantly (rank 2 of 11, +5.65pts vs SPY over 5 days), suggesting the ~10% drop in BIO is idiosyncratic rather than sector-wide, adding a negative signal. The macro environment is also unfavorable with the 10Y at 5.19% (above the 4.5% threshold) and today's broad market selloff (SPY -1.14%, VXX +9.13%).
!Oct 16, 3:21 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO (Bio-Rad Laboratories) is down ~10.1% from its 30-day high, a modest and plausible dip without confirmed fundamental impairment — the SEC filings show no adverse metrics and there are no negative headlines. However, the dominant risk factor here is imminent earnings on 2026-10-27 (11 days away), which is a binary event that the framework explicitly treats as a default-skip unless other evidence is unusually strong. No confirming signals exist: zero insider buys, no options flow data, and no analyst upgrades post-drop. Today's broad market sell-off (SPY -1.14%, QQQ -2.44%, VXX +9.13%) partially explains the dip, but Health Care is actually outperforming (rank 2 of 11, +5.65pts vs SPY over 5 days), meaning BIO is underperforming its own sector — a mild idiosyncratic negative. The 10Y at 5.19% is a structural headwind. With no confirmation signals and imminent earnings risk, this setup does not clear the bar.
?Oct 16, 2:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 3.03% intraday, representing meaningful selling pressure and real institutional flow. There are no headlines to explain the move, but absence of news does not negate the momentum signal. The macro backdrop (elevated mortgage rates at 7.4%, 3.3σ above trend) is not directly sector-relevant for BIO (biotech/life sciences), so it neither supports nor undermines continuation. With 75 minutes remaining until the forced close, there is moderate time for the move to extend, but not ample runway. The lack of a clear catalyst raises the possibility this is a technical or basket-driven flush that could stabilize or partially reverse into the close. No reversal pattern is evident from the data provided, and the initial move size (-3.03%) is on the higher end of meaningful intraday moves, suggesting some exhaustion risk. On balance, momentum slightly favors continuation to the downside, but conviction is low — this is a borderline read resolved in favor of the trade per system rules.
!Oct 16, 2:30 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 3.03% intraday, representing meaningful selling pressure and real institutional flow. There are no headlines to explain the move, but absence of news does not negate the momentum signal. The macro backdrop (elevated mortgage rates at 7.4%, 3.3σ above trend) is not directly sector-relevant for BIO (biotech/life sciences), so it neither supports nor undermines continuation. With 75 minutes remaining until the forced close, there is moderate time for the move to extend, but not ample runway. The lack of a clear catalyst raises the possibility this is a technical or basket-driven flush that could stabilize or partially reverse into the close. No reversal pattern is evident from the data provided, and the initial move size (-3.03%) is on the higher end of meaningful intraday moves, suggesting some exhaustion risk. On balance, momentum slightly favors continuation to the downside, but conviction is low — this is a borderline read resolved in favor of the trade per system rules.
?Oct 16, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.64% today, a modest but real move suggesting some selling pressure. However, several factors keep conviction limited: (1) The move is below the 2-5% threshold that would represent strong directional conviction, making it less clear whether this is sustained selling or noise. (2) No news catalyst is present to explain the move or sustain further selling. (3) The macro context — elevated mortgage rates at 7.4 (3.3σ above trend) — is most relevant to Homebuilders, REITs, and Banks, not life science tools/diagnostics (BIO's sector), so macro headwinds are indirect at best. (4) With 330 minutes remaining (full session still ahead), there is ample time for continuation but also for mean reversion. (5) Without a clear fundamental driver or strong magnitude, the base case is mild continuation momentum consistent with the system's default lean. Probability sits at the boundary — no strong reason to expect a fade, but also no strong reason to call high-conviction continuation.
!Oct 16, 10:16 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is down 1.64% today, a modest but real move suggesting some selling pressure. However, several factors keep conviction limited: (1) The move is below the 2-5% threshold that would represent strong directional conviction, making it less clear whether this is sustained selling or noise. (2) No news catalyst is present to explain the move or sustain further selling. (3) The macro context — elevated mortgage rates at 7.4 (3.3σ above trend) — is most relevant to Homebuilders, REITs, and Banks, not life science tools/diagnostics (BIO's sector), so macro headwinds are indirect at best. (4) With 330 minutes remaining (full session still ahead), there is ample time for continuation but also for mean reversion. (5) Without a clear fundamental driver or strong magnitude, the base case is mild continuation momentum consistent with the system's default lean. Probability sits at the boundary — no strong reason to expect a fade, but also no strong reason to call high-conviction continuation.
?Oct 9, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 1.75% today with no attributable news catalyst. The move is meaningful but not outsized. The critical issue is time: only 10 minutes remain before the 3:45 PM ET forced close, which severely limits the runway for continuation. With such a short window, even a well-supported momentum setup has little time to extend materially toward the +3% profit target, while the -1.5% stop remains a real risk if late-session profit-taking or end-of-day rebalancing hits. The macro context (elevated mortgage rates) is irrelevant to BIO (a life sciences/biotech company), providing no tailwind or headwind. The absence of news is neutral per guidance, but the combination of minimal time remaining and no identifiable catalyst driving the move leads me to assign a sub-0.5 probability. The risk/reward of entering with 10 minutes left is asymmetrically unfavorable — not enough time to capture the target but full stop-loss exposure remains. Lean toward no trade.
!Oct 9, 3:35 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 1.75% today with no attributable news catalyst. The move is meaningful but not outsized. The critical issue is time: only 10 minutes remain before the 3:45 PM ET forced close, which severely limits the runway for continuation. With such a short window, even a well-supported momentum setup has little time to extend materially toward the +3% profit target, while the -1.5% stop remains a real risk if late-session profit-taking or end-of-day rebalancing hits. The macro context (elevated mortgage rates) is irrelevant to BIO (a life sciences/biotech company), providing no tailwind or headwind. The absence of news is neutral per guidance, but the combination of minimal time remaining and no identifiable catalyst driving the move leads me to assign a sub-0.5 probability. The risk/reward of entering with 10 minutes left is asymmetrically unfavorable — not enough time to capture the target but full stop-loss exposure remains. Lean toward no trade.
?Oct 8, 1:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.52% intraday with no attributable headlines, suggesting technical or broad market selling pressure rather than a specific catalyst. The macro context (elevated mortgage rates at 7.4%, 3.8σ above trend) primarily impacts Homebuilders, REITs, and Banks — not life sciences/biotech — so macro offers neither tailwind nor headwind for BIO specifically. With 130 minutes remaining there is meaningful time for continuation, but the absence of a news catalyst makes it harder to assess whether this is sustained institutional selling or a temporary dislocation. The move is at the lower bound of 'meaningful' (2.5%), which could reflect either real conviction or an overreaction seeking mean reversion. No reversal signals are evident, and no thin-volume warning is present. Given the bounded risk profile of the system and no clear reason to expect a fade, continuation is marginally favored, but this is a borderline read with no strong directional edge beyond the momentum itself.
!Oct 8, 1:35 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.52% intraday with no attributable headlines, suggesting technical or broad market selling pressure rather than a specific catalyst. The macro context (elevated mortgage rates at 7.4%, 3.8σ above trend) primarily impacts Homebuilders, REITs, and Banks — not life sciences/biotech — so macro offers neither tailwind nor headwind for BIO specifically. With 130 minutes remaining there is meaningful time for continuation, but the absence of a news catalyst makes it harder to assess whether this is sustained institutional selling or a temporary dislocation. The move is at the lower bound of 'meaningful' (2.5%), which could reflect either real conviction or an overreaction seeking mean reversion. No reversal signals are evident, and no thin-volume warning is present. Given the bounded risk profile of the system and no clear reason to expect a fade, continuation is marginally favored, but this is a borderline read with no strong directional edge beyond the momentum itself.
?Oct 8, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BIO is down 10.4% from its 30-day high with no headlines, no fundamental deterioration visible in recent filings, and no insider selling — suggesting the drop is sector/macro-driven rather than idiosyncratic. However, earnings are 19 days away (within the 15-30 day headwind window), which creates a meaningful binary risk overhang and contributes a -1 signal. The options flow is unusual but muted in absolute terms (low volumes, z-scores deeply negative), and the P/C ratio of 0.52 is not strongly bullish. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1), but the 10Y yield at 5.27% is a structural headwind (+1 negative), and the T5YIFR printing 1.8σ above trend adds rate pressure. Net signal score: sector underperformance (+1), earnings in 15-30 days (-1), high 10Y yield (-1), drop <15% (no bonus), no cluster buy, no strong call flow = net -1, pushing below the buy threshold despite no fundamental impairment.
!Oct 8, 12:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BIO is down 10.4% from its 30-day high with no headlines, no fundamental deterioration visible in recent filings, and no insider selling — suggesting the drop is sector/macro-driven rather than idiosyncratic. However, earnings are 19 days away (within the 15-30 day headwind window), which creates a meaningful binary risk overhang and contributes a -1 signal. The options flow is unusual but muted in absolute terms (low volumes, z-scores deeply negative), and the P/C ratio of 0.52 is not strongly bullish. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1), but the 10Y yield at 5.27% is a structural headwind (+1 negative), and the T5YIFR printing 1.8σ above trend adds rate pressure. Net signal score: sector underperformance (+1), earnings in 15-30 days (-1), high 10Y yield (-1), drop <15% (no bonus), no cluster buy, no strong call flow = net -1, pushing below the buy threshold despite no fundamental impairment.
?Oct 8, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO is down 10.4% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider sales, and SEC filings show empty metrics, leaving the cause of the drop unclear but potentially macro/sector-driven (Health Care is underperforming SPY by 5.17pts over 30 days). Options flow is unusually low in absolute volume (both calls and puts deeply negative z-scores), suggesting thin market participation rather than informed directional conviction. The stock does have an upcoming earnings report in 19 days, which elevates binary risk and argues for caution per the scoring framework.
!Oct 8, 12:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO is down 10.4% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider sales, and SEC filings show empty metrics, leaving the cause of the drop unclear but potentially macro/sector-driven (Health Care is underperforming SPY by 5.17pts over 30 days). Options flow is unusually low in absolute volume (both calls and puts deeply negative z-scores), suggesting thin market participation rather than informed directional conviction. The stock does have an upcoming earnings report in 19 days, which elevates binary risk and argues for caution per the scoring framework.
?Oct 8, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BIO is down 10.4% from its 30-day high with no headlines, no fundamental deterioration visible in recent filings, and no insider selling — suggesting the drop is sector/macro-driven rather than idiosyncratic. However, earnings are 19 days away (within the 15-30 day headwind window), which creates a meaningful binary risk overhang and contributes a -1 signal. The options flow is unusual but muted in absolute terms (low volumes, z-scores deeply negative), and the P/C ratio of 0.52 is not strongly bullish. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1), but the 10Y yield at 5.27% is a structural headwind (+1 negative), and the T5YIFR printing 1.8σ above trend adds rate pressure. Net signal score: sector underperformance (+1), earnings in 15-30 days (-1), high 10Y yield (-1), drop <15% (no bonus), no cluster buy, no strong call flow = net -1, pushing below the buy threshold despite no fundamental impairment.
!Oct 8, 11:21 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BIO is down 10.4% from its 30-day high with no headlines, no fundamental deterioration visible in recent filings, and no insider selling — suggesting the drop is sector/macro-driven rather than idiosyncratic. However, earnings are 19 days away (within the 15-30 day headwind window), which creates a meaningful binary risk overhang and contributes a -1 signal. The options flow is unusual but muted in absolute terms (low volumes, z-scores deeply negative), and the P/C ratio of 0.52 is not strongly bullish. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1), but the 10Y yield at 5.27% is a structural headwind (+1 negative), and the T5YIFR printing 1.8σ above trend adds rate pressure. Net signal score: sector underperformance (+1), earnings in 15-30 days (-1), high 10Y yield (-1), drop <15% (no bonus), no cluster buy, no strong call flow = net -1, pushing below the buy threshold despite no fundamental impairment.
?Oct 8, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO is down 10.4% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider sales, and SEC filings show empty metrics, leaving the cause of the drop unclear but potentially macro/sector-driven (Health Care is underperforming SPY by 5.17pts over 30 days). Options flow is unusually low in absolute volume (both calls and puts deeply negative z-scores), suggesting thin market participation rather than informed directional conviction. The stock does have an upcoming earnings report in 19 days, which elevates binary risk and argues for caution per the scoring framework.
!Oct 8, 11:21 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO is down 10.4% from its 30-day high with no identifiable fundamental catalyst — no negative headlines, no insider sales, and SEC filings show empty metrics, leaving the cause of the drop unclear but potentially macro/sector-driven (Health Care is underperforming SPY by 5.17pts over 30 days). Options flow is unusually low in absolute volume (both calls and puts deeply negative z-scores), suggesting thin market participation rather than informed directional conviction. The stock does have an upcoming earnings report in 19 days, which elevates binary risk and argues for caution per the scoring framework.
?Oct 8, 10:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.86% today with no headline catalyst, suggesting this is flow/macro-driven selling rather than a news event that could be faded on resolution. The macro context shows the 5-year forward inflation rate (T5YIFR) is elevated at 1.8σ above trend — this pressures rate-sensitive and growth/biotech sectors broadly, providing a tailwind for continued selling pressure. With 305 minutes remaining (well over half the session), there is ample time for the move to extend. However, the setup is not high-conviction: no news confirms the thesis, the move is on the lower end of the 'meaningful' threshold at ~2.86%, and the macro factor is indirect rather than a direct BIO-specific catalyst. No clear reversal signal is present (no fade off lows described, no abnormal volume warning). On balance, the absence of a reversal catalyst combined with supportive macro pressure and sufficient time remaining tips continuation probability slightly above 0.5, but this is a borderline read.
!Oct 8, 10:40 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is down 2.86% today with no headline catalyst, suggesting this is flow/macro-driven selling rather than a news event that could be faded on resolution. The macro context shows the 5-year forward inflation rate (T5YIFR) is elevated at 1.8σ above trend — this pressures rate-sensitive and growth/biotech sectors broadly, providing a tailwind for continued selling pressure. With 305 minutes remaining (well over half the session), there is ample time for the move to extend. However, the setup is not high-conviction: no news confirms the thesis, the move is on the lower end of the 'meaningful' threshold at ~2.86%, and the macro factor is indirect rather than a direct BIO-specific catalyst. No clear reversal signal is present (no fade off lows described, no abnormal volume warning). On balance, the absence of a reversal catalyst combined with supportive macro pressure and sufficient time remaining tips continuation probability slightly above 0.5, but this is a borderline read.
?Oct 6, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.16% intraday with no attributable headline, suggesting institutional flow or sector rotation is driving the move rather than a fade-prone news spike. The macro context shows 5-year forward inflation expectations elevated at 2.0σ above trend — this is modestly negative for rate-sensitive names but BIO as a life sciences tools/biotech company is not the most rate-sensitive sector, so the macro headwind is limited. With 360 minutes remaining there is ample time for continuation, and the move size (2.16%) is meaningful but not exhausted. No reversal signals or news-driven overshoot evident. Absent a clear fade catalyst, the system bias favors continuation at a modest probability slightly above the neutral threshold.
!Oct 6, 9:45 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
BIO is up 2.16% intraday with no attributable headline, suggesting institutional flow or sector rotation is driving the move rather than a fade-prone news spike. The macro context shows 5-year forward inflation expectations elevated at 2.0σ above trend — this is modestly negative for rate-sensitive names but BIO as a life sciences tools/biotech company is not the most rate-sensitive sector, so the macro headwind is limited. With 360 minutes remaining there is ample time for continuation, and the move size (2.16%) is meaningful but not exhausted. No reversal signals or news-driven overshoot evident. Absent a clear fade catalyst, the system bias favors continuation at a modest probability slightly above the neutral threshold.
?Oct 2, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 3.41% with only 10 minutes remaining until the forced close. The move is meaningful and represents real conviction, but the extreme time constraint is the dominant factor here — there is simply insufficient runway for further continuation before the 3:45 PM ET cutoff. With only 10 minutes left, the risk of end-of-day profit-taking and position flattening by other participants is elevated, and the 3% profit target becomes very difficult to achieve. The macro context (5Y5Y forward inflation at 2.0σ above trend) is mildly unfavorable for rate-sensitive names but not a strong directional catalyst either way. No headlines are present to explain or sustain the move. Given the near-zero time remaining, the probability of meaningful upside continuation is below the 0.5 threshold — not because of a strong fade signal, but because the clock has effectively expired on the opportunity.
!Oct 2, 3:35 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
BIO is up 3.41% with only 10 minutes remaining until the forced close. The move is meaningful and represents real conviction, but the extreme time constraint is the dominant factor here — there is simply insufficient runway for further continuation before the 3:45 PM ET cutoff. With only 10 minutes left, the risk of end-of-day profit-taking and position flattening by other participants is elevated, and the 3% profit target becomes very difficult to achieve. The macro context (5Y5Y forward inflation at 2.0σ above trend) is mildly unfavorable for rate-sensitive names but not a strong directional catalyst either way. No headlines are present to explain or sustain the move. Given the near-zero time remaining, the probability of meaningful upside continuation is below the 0.5 threshold — not because of a strong fade signal, but because the clock has effectively expired on the opportunity.
?Oct 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BIO is down 10.1% from its 30-day high, which is below the +1 threshold of >=15% drop, and there is no fundamental deterioration visible in the sparse 10-Q/8-K filings (empty metrics). However, earnings are 26 days away, triggering the -1 headwind signal for uncertainty premium. The macro environment is a net negative: 10Y at 5.26% is well above the 4.5% threshold (-1), and the 5-year forward inflation rate is running 2.0σ above trend, adding rate-sensitive pressure. The sector (Health Care) has modest near-term strength but slightly underperforms on 30d basis, offering only a marginal offset. No insider buying, no unusual options flow, and no news headlines leave the signal stack thin, netting approximately -2 to -3, which falls below the buy threshold.
!Oct 2, 7:01 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
BIO is down 10.1% from its 30-day high, which is below the +1 threshold of >=15% drop, and there is no fundamental deterioration visible in the sparse 10-Q/8-K filings (empty metrics). However, earnings are 26 days away, triggering the -1 headwind signal for uncertainty premium. The macro environment is a net negative: 10Y at 5.26% is well above the 4.5% threshold (-1), and the 5-year forward inflation rate is running 2.0σ above trend, adding rate-sensitive pressure. The sector (Health Care) has modest near-term strength but slightly underperforms on 30d basis, offering only a marginal offset. No insider buying, no unusual options flow, and no news headlines leave the signal stack thin, netting approximately -2 to -3, which falls below the buy threshold.
?Oct 2, 7:00 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO is down 10.1% from its 30-day high with no confirming negative catalysts — no adverse headlines, no insider selling, and no unusual put flow. The drop appears to be macro/sector-driven rather than fundamentally impaired, as Health Care (XLV) has slightly underperformed SPY over 30 days. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, empty 10-Q metrics), leaving the thesis resting on the absence of bad news rather than positive evidence. Earnings in 26 days introduce elevated binary risk that limits upside confidence in the 90-day window.
!Oct 2, 7:00 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO is down 10.1% from its 30-day high with no confirming negative catalysts — no adverse headlines, no insider selling, and no unusual put flow. The drop appears to be macro/sector-driven rather than fundamentally impaired, as Health Care (XLV) has slightly underperformed SPY over 30 days. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, empty 10-Q metrics), leaving the thesis resting on the absence of bad news rather than positive evidence. Earnings in 26 days introduce elevated binary risk that limits upside confidence in the 90-day window.
?Oct 1, 6:02 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 10.3% drawdown from the 30-day high is moderate and no company-specific negative catalysts (guidance cuts, accounting issues, or operational deterioration) are evident in the available news or SEC filings. The 10-Q and 8-K filings from August 2026 lack detailed metrics, preventing deep fundamental assessment, but the absence of negative disclosures is a mild positive. The primary headwind is macro: the 5-year forward inflation rate (T5YIFR) is printing 2.0σ above its 24-month trend, suggesting rate-sensitive pressure that could weigh on valuation-rich life science instrumentation companies like Bio-Rad.
!Oct 1, 6:02 PMsignalseverity 0.10
Agent 4 — Dip Buyer (Frozen) — dip_skipped
The 10.3% drawdown from the 30-day high is moderate and no company-specific negative catalysts (guidance cuts, accounting issues, or operational deterioration) are evident in the available news or SEC filings. The 10-Q and 8-K filings from August 2026 lack detailed metrics, preventing deep fundamental assessment, but the absence of negative disclosures is a mild positive. The primary headwind is macro: the 5-year forward inflation rate (T5YIFR) is printing 2.0σ above its 24-month trend, suggesting rate-sensitive pressure that could weigh on valuation-rich life science instrumentation companies like Bio-Rad.
?Oct 1, 4:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO is down 10.1% from its 30-day high with no confirming negative catalysts — no adverse headlines, no insider selling, and no unusual put flow. The drop appears to be macro/sector-driven rather than fundamentally impaired, as Health Care (XLV) has slightly underperformed SPY over 30 days. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, empty 10-Q metrics), leaving the thesis resting on the absence of bad news rather than positive evidence. Earnings in 26 days introduce elevated binary risk that limits upside confidence in the 90-day window.
!Oct 1, 4:21 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
BIO is down 10.1% from its 30-day high with no confirming negative catalysts — no adverse headlines, no insider selling, and no unusual put flow. The drop appears to be macro/sector-driven rather than fundamentally impaired, as Health Care (XLV) has slightly underperformed SPY over 30 days. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, empty 10-Q metrics), leaving the thesis resting on the absence of bad news rather than positive evidence. Earnings in 26 days introduce elevated binary risk that limits upside confidence in the 90-day window.
?Oct 1, 4:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BIO is down 10.1% from its 30-day high, which is below the +1 threshold of >=15% drop, and there is no fundamental deterioration visible in the sparse 10-Q/8-K filings (empty metrics). However, earnings are 26 days away, triggering the -1 headwind signal for uncertainty premium. The macro environment is a net negative: 10Y at 5.26% is well above the 4.5% threshold (-1), and the 5-year forward inflation rate is running 2.0σ above trend, adding rate-sensitive pressure. The sector (Health Care) has modest near-term strength but slightly underperforms on 30d basis, offering only a marginal offset. No insider buying, no unusual options flow, and no news headlines leave the signal stack thin, netting approximately -2 to -3, which falls below the buy threshold.
?Oct 1, 2:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
BIO is down 10.1% from its 30-day high with no confirming negative catalysts — no adverse headlines, no insider selling, and no unusual put flow. The drop appears to be macro/sector-driven rather than fundamentally impaired, as Health Care (XLV) has slightly underperformed SPY over 30 days. However, confirmation signals are entirely absent (no insider buys, no unusual call flow, empty 10-Q metrics), leaving the thesis resting on the absence of bad news rather than positive evidence. Earnings in 26 days introduce elevated binary risk that limits upside confidence in the 90-day window.
?Oct 1, 2:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
BIO is down 10.1% from its 30-day high, which is below the +1 threshold of >=15% drop, and there is no fundamental deterioration visible in the sparse 10-Q/8-K filings (empty metrics). However, earnings are 26 days away, triggering the -1 headwind signal for uncertainty premium. The macro environment is a net negative: 10Y at 5.26% is well above the 4.5% threshold (-1), and the 5-year forward inflation rate is running 2.0σ above trend, adding rate-sensitive pressure. The sector (Health Care) has modest near-term strength but slightly underperforms on 30d basis, offering only a marginal offset. No insider buying, no unusual options flow, and no news headlines leave the signal stack thin, netting approximately -2 to -3, which falls below the buy threshold.
?Oct 1, 12:50 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 4.28% today with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven event. The move is meaningful in magnitude and likely represents real flow. However, several factors temper conviction: (1) At 175 minutes remaining, there is ample time for a mean-reversion attempt, but also enough time for continuation if sellers remain in control. (2) The macro context shows the 5-year forward inflation rate (T5YIFR) printing 2.0σ above trend, which pressures rate-sensitive and growth-oriented sectors broadly — BIO as a life sciences/biotech name could face continued headwinds from this elevated rate expectations environment. (3) No news means no catalyst for a snap-back reversal, which slightly favors continuation. (4) A 4%+ move without news often reflects portfolio-level rebalancing or risk-off rotation, which can persist into the close. Balancing the meaningful downside move and supportive macro headwind against the absence of news specificity and moderate time remaining, a slight lean toward continuation is appropriate, but confidence is modest.
?Oct 1, 11:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 3.32% today with no attributable headline, suggesting this is flow-driven selling — possibly sector rotation or institutional repositioning. With 280 minutes remaining (roughly 4.5 hours), there is ample time for the move to continue into the close. The macro context shows the 5-year forward inflation rate (T5YIFR) is elevated at 2.0σ above trend, which broadly pressures rate-sensitive and growth sectors; biotech (BIO) can be sensitive to rate expectations given its long-duration earnings profile, providing mild macro tailwind for continued selling pressure. However, the absence of any news headline makes it harder to assign high conviction — without a catalyst, intraday moves of this magnitude can attract dip buyers in the afternoon session. No reversal signal is evident from the data provided. Overall, the evidence modestly favors continuation of the downward move — momentum is real, macro is unsupportive, and time is ample — but the lack of a news driver and potential for mean-reversion buying keeps confidence modest. Assigning 0.52 continuation probability to the downside.
?Sep 25, 3:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.55% with only 20 minutes remaining until the forced close. The move is meaningful in magnitude, suggesting real selling pressure, but the critical constraint here is time: with just 20 minutes left, there is very limited runway for continuation even if the thesis is correct. The macro context shows elevated 5Y5Y inflation forwards (1.6σ above trend), which is mildly negative for rate-sensitive and growth-oriented names like BIO (biotech), providing some fundamental tailwind to the bearish thesis. However, no headlines are present to explain the move, and late-session dynamics often include mean-reversion flows, short covering, and market-on-close buy imbalances from passive rebalancing — all of which would work against continuation of a down move in the final 20 minutes. The combination of very limited time remaining, absence of a news catalyst to sustain momentum, and typical EOD mean-reversion tendencies in the absence of a clear driver pushes the probability below the 0.5 threshold. Not taking the position.
?Sep 25, 10:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.59% today, which is a moderate but not outsized move. With 290 minutes remaining (nearly a full session still ahead), there is ample time for continuation or reversal. However, several factors temper the continuation case: (1) The macro context shows 5Y5Y forward inflation (T5YIFR) running 1.6σ above trend at 2.33, which signals elevated rate expectations — this is a headwind for rate-sensitive and growth-oriented names like BIO (biotech/life sciences), but it is a general macro drag rather than a fresh catalyst driving today's specific move. (2) There are no news headlines to explain the selloff, which means we cannot confirm whether this is fundamental selling with conviction or a noise/liquidity-driven drift. Absence of news cuts both ways, but without a clear catalyst the move may lack the conviction needed to sustain into close. (3) At -1.59%, the move is meaningful but sits at the lower end of the 2-5% 'real flow' range — it does not yet signal high-conviction institutional pressure. (4) With 290 minutes remaining, there is time for the move to develop, but also significant time for mean reversion. Balancing these factors — moderate macro headwind, no news catalyst, moderate move size — this setup does not clear the 0.5 continuation threshold with sufficient confidence to trigger a position.
?Sep 25, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.53% today, which is a moderate but not dramatic move. At 355 minutes remaining (still early in the session), there is ample time for the move to continue or reverse. The macro context shows the 5-year forward inflation rate 1.6σ above trend, which is mildly bearish for rate-sensitive sectors — biotech/life sciences names like BIO can be rate-sensitive given their long-duration growth profiles, providing a modest tailwind for the downside continuation thesis. However, the move is only 1.53%, which is below the 2-5% threshold where momentum becomes compelling evidence of institutional conviction. No news catalyst is present to confirm directional flow. With no reversal signal, no thin volume indication, and a macro environment that is mildly supportive of the downward direction, the base case is a coin-flip leaning slightly toward continuation per the system's tiebreaker rules. Assigning 0.50 — the move lacks the magnitude or macro clarity to warrant higher conviction, but there is no affirmative reason to expect a fade either.
?Sep 24, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.61% today with only 10 minutes remaining until the forced close. The move is meaningful in magnitude and suggests real buying interest, but the extreme time constraint is the dominant factor here — there is simply not enough runway for continuation to add meaningful value, and the risk of a late-session fade or mean reversion in the final minutes is elevated. No catalytic headlines are present to sustain momentum. The macro context (T5YIFR elevated at 2.0σ above trend) suggests rate-sensitive sectors face headwinds, and BIO as a biotech/life sciences name can be indirectly sensitive to rate dynamics affecting growth/discount-rate valuations. With only 10 minutes left, even a valid momentum setup has insufficient time to reach a +3% profit target from current levels without excessive risk. Probability set below 0.5 primarily due to time exhaustion.
?Sep 18, 2:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.63% today, which is a moderate but not outsized move. Key headwinds to continuation: (1) Only 60 minutes remain until forced close, limiting runway for further downside to develop. (2) No news catalyst is present to sustain directional flow — the move may simply be sector rotation or light selling pressure rather than an informed trade. (3) The macro context shows T5YIFR elevated at 1.8σ above trend, which signals rate-sensitive pressure broadly, but BIO (Bio-Rad Laboratories) as a life sciences tools company is not among the most rate-sensitive names — this macro signal has limited direct bearing. (4) A -1.63% move is meaningful but sits just below the 2% threshold that typically signals strong institutional conviction. (5) With limited time and no confirming catalyst, mean-reversion risk into the close is elevated — late-session buyers often step in on moderate pullbacks in quality names. On balance, the evidence does not support a high-confidence continuation trade, and the probability of further downside into the close falls slightly below the 0.5 trigger threshold.
?Sep 15, 11:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 3.22% today with no attributable headline, suggesting institutional or systematic flow rather than a news-driven spike that might fade quickly. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) 230 minutes remaining is actually ample time — not a constraint — but it also means more time for the move to mean-revert if it was driven by a single large order now exhausted; (2) the macro backdrop shows 5Y5Y forward inflation (T5YIFR) running 1.8σ above trend, which signals elevated rate expectations — BIO as a biotech/life sciences play can be rate-sensitive (growth/duration characteristics), and an elevated inflation forward rate environment is a mild headwind for the sector; (3) absence of any news catalyst means we cannot confirm a fundamental re-rating is underway. Balancing these: the base rate for continuation of a ~3% intraday move is modestly above 50%, there is no clear reversal signal present, and the system's bounded risk profile (1.5% stop, 3% target) favors taking borderline reads. Assigning a slight lean toward continuation without strong conviction.
?Sep 14, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distribution story. The stock peaked at $390.34 on 2026-08-25 on 296K volume and has since traced a persistent down-and-right arc: by 2026-09-10 price had fallen to $368.75 on the heaviest down-day volume in the window (334K), followed by today's (2026-09-11) marginal +0.15% recovery on 345K — the highest volume in the entire 20-day sample — that failed to reclaim any meaningful ground. Critically, the dominant down-leg from Aug 28 through Sep 11 is characterized by expanding volume on red days (207K → 301K → 256K → 334K → 345K), while the brief up-day on Sep 2 ($388.51, 285K) could not hold and was immediately reversed on lighter, then heavier, selling volume. The SIR path has drifted decisively down-and-right, the hallmark of institutional distribution under the cover of price stabilization near the cluster low. Risks: A multi-session reclaim of the $385–$390 zone on volume above 300K would invalidate the distribution read and suggest the selling pressure has been absorbed. Additionally, macro regime shift — e.g., a sharp steepening of the yield curve beyond the current 0.33 T10Y2Y reading — could act as a sector tailwind for Health Care defensives and lift BIO out of the pattern before the distribution fully resolves.
?Sep 10, 3:36 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 10 minutes remaining until the forced close, there is minimal time for continuation to develop meaningfully. The -1.97% move is at the lower end of the 2-5% meaningful-flow threshold, so conviction signal is moderate at best. No news catalyst is present to sustain selling pressure into the close. The macro context (elevated 5Y5Y inflation forward rate, 1.6σ above trend) is mildly rate-sensitive headwind for broad equities but is not a strong BIO-specific driver — biotech is not the most rate-sensitive sector. With 10 minutes left, late-session dynamics tend toward mean reversion or stabilization as algorithms and market makers square books. The combination of very short time horizon, no news fuel, and moderate (not extreme) move magnitude pushes the probability below 0.5, favoring a fade or flat close rather than further downside.
?Sep 10, 1:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 1.58% today, which is a meaningful but not dramatic intraday move. No headlines are available to explain the move, so we cannot identify a catalyst with further legs. The macro context shows elevated 5-year forward inflation expectations (T5YIFR at 1.6σ above trend), which is a headwind for rate-sensitive and growth-oriented names — BIO as a life sciences company could face modest pressure here, but the effect is diffuse and not sector-specific enough to be a strong directional driver. With 140 minutes remaining there is ample time for continuation, but also ample time for a mean-reversion into the close as institutional desks opportunistically buy the dip on a name with no apparent fundamental deterioration. The move is below the 2% threshold where momentum tends to self-reinforce, and absent volume data or a clear catalyst, the balance of evidence leans slightly toward fade rather than continuation. Probability set just below 0.5 to avoid triggering a position given weak conviction.
?Sep 10, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down 2.03% with 355 minutes remaining — a meaningful move with ample time to develop further. No headlines to attribute the move to, which is neutral per guidance. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend, which is modestly bearish for rate-sensitive sectors broadly, though BIO (Bio-Rad Laboratories) as a life sciences/tools company has moderate rate sensitivity. The move magnitude is at the lower bound of the 2-5% meaningful flow range, suggesting real selling but not extreme conviction. With no news catalyst, no clear reversal signal, and time remaining substantial, the base case is mild continuation of the downward momentum into the close. However, without stronger volume confirmation data or a clearer macro/sector headwind specific to this name, conviction is limited. Assigning baseline continuation probability at 0.5 — the momentum bias tips it just to the continuation side, but this is a borderline read.
?Sep 4, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is down -1.84% today, a moderate but meaningful intraday move suggesting real selling flow. However, several factors temper continuation confidence: (1) No news catalyst identified, so the move lacks an obvious fundamental driver that would sustain selling into the close. (2) The macro context shows 5Y5Y forward inflation (T5YIFR) elevated at 1.7σ above trend — this is rate-sensitive broadly, and BIO as a life sciences/biotech name is somewhat rate-sensitive, but the signal is ambiguous in direction for this specific ticker. (3) With 330 minutes remaining (essentially the full afternoon session), there is ample time for either continuation or reversal, which is neutral. (4) A -1.84% move sits at the lower end of the 2-5% 'meaningful conviction' range, so momentum signal is present but not strong. (5) Absence of headlines means no catalyst to anchor sellers or attract new selling. Balancing these factors: the move has real flow behind it but lacks the news, macro tailwind, or magnitude to confidently project sustained selling. Sitting at the minimum threshold for a trade signal.
?Sep 2, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 1.70% today, a moderate but meaningful intraday move suggesting real buying flow. There are no news catalysts to explain or invalidate the move, which is typical — absence of news does not argue against continuation. The macro context shows the 5Y5Y forward inflation rate elevated at 1.7σ above trend, which is modestly negative for rate-sensitive sectors broadly, but life sciences / biotech tools companies like BIO are not the most acutely rate-sensitive names, so this headwind is mild. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend, which supports taking the trade. The move is below the 2% threshold that would signal strong conviction, so I'm not elevating this to a high-confidence read. No reversal signals are evident from the data provided. Overall, a modest lean toward continuation with bounded downside via the system's stop discipline.
?Aug 25, 3:31 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
BIO is up 2.04% today with only 15 minutes remaining until the forced close. The extremely limited time horizon is the dominant factor here — even if momentum is genuine, there is simply insufficient runway for the +3% profit target to be reached from current levels, and late-session mean reversion or profit-taking is common in the final 15 minutes. The macro context shows elevated 5Y5Y inflation expectations (1.8σ above trend), which creates a mildly unfavorable backdrop for rate-sensitive sectors, though BIO as a life sciences company is not the most rate-sensitive name. No news catalyst is present to explain the move, which is neutral per the framework but combined with the very short time window makes continuation less compelling. The move magnitude (2.04%) is meaningful and suggests real flow, but with 15 minutes left and no fresh catalyst, the risk of a fade into the close outweighs the continuation case. Probability set below 0.5 primarily on time constraint — this same setup with 60+ minutes remaining would warrant 0.52-0.55.

← Back to dashboard